Edoxaban – Medxy AI

Rethinking Rhythm Control for Secondary Stroke Prevention: Insights from the STABLED Randomized Clinical Trial

By MedXY 03/06/2026

This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.

Cardiology Neurology news

Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial

By MedXY 03/02/2026

The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a recent history of ischemic stroke.

Cardiology news

Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation

By MedXY 01/03/2026

A hierarchical win ratio analysis of the NOAH-AFNET 6 trial confirms that edoxaban does not provide a net clinical benefit over no anticoagulation in patients with device-detected atrial fibrillation, primarily due to the balance between low stroke rates and significant bleeding risks.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.

Cardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

By MedXY 08/17/2025

The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.